These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 24146095)

  • 21. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventing bone complications in prostate cancer.
    Bishr M; Saad F
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):299-303. PubMed ID: 22871982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skeletal complications of rheumatoid arthritis.
    Heinlen L; Humphrey MB
    Osteoporos Int; 2017 Oct; 28(10):2801-2812. PubMed ID: 28779302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
    Lipton A; Uzzo R; Amato RJ; Ellis GK; Hakimian B; Roodman GD; Smith MR
    J Natl Compr Canc Netw; 2009 Oct; 7 Suppl 7(Suppl 7):S1-29; quiz S30. PubMed ID: 19878635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates for advanced prostate cancer.
    Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone-modifying Agents (BMAs) in Breast Cancer.
    Shapiro CL
    Clin Breast Cancer; 2021 Oct; 21(5):e618-e630. PubMed ID: 34045175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
    Wang Z; Qiao D; Lu Y; Curtis D; Wen X; Yao Y; Zhao H
    Oncologist; 2015 Apr; 20(4):440-9. PubMed ID: 25732263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates and other bone agents for breast cancer.
    O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates for advanced prostate cancer.
    Macherey S; Monsef I; Jahn F; Jordan K; Yuen KK; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006250. PubMed ID: 29278410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
    Carter JA; Joshi AD; Kaura S; Botteman MF
    Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in management of bone disease in breast cancer.
    Walkington L; Coleman RE
    Bone; 2011 Jan; 48(1):80-7. PubMed ID: 20621652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
    J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
    Gaudio A; Xourafa A; Rapisarda R; Castellino P
    Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone metastases and bone loss medical treatment in prostate cancer patients.
    Safriadi F
    Acta Med Indones; 2013 Jan; 45(1):76-80. PubMed ID: 23585414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults.
    van den Blink QU; Garcez K; Henson CC; Davidson SE; Higham CE
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010604. PubMed ID: 29683475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of bisphosphonates in the adjuvant setting for breast cancer.
    Reeder JG; Brufsky AM
    Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
    Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
    Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.